• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status.

作者信息

Rose C, Mouridsen H T, Thorpe S M, Andersen J, Blichert-Toft M, Andersen K W

出版信息

World J Surg. 1985 Oct;9(5):765-74. doi: 10.1007/BF01655192.

DOI:10.1007/BF01655192
PMID:4060747
Abstract
摘要

相似文献

1
Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status.对具有高复发风险的绝经后乳腺癌患者进行抗雌激素治疗：72个月的生命表分析及类固醇激素受体状态
World J Surg. 1985 Oct;9(5):765-74. doi: 10.1007/BF01655192.
2
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.他莫昔芬辅助治疗可手术乳腺癌。那不勒斯（GUN）研究的10年结果。
Lancet. 1988 Nov 12;2(8620):1095-9.
3
Antiestrogen treatment of postmenopausal women with primary high risk breast cancer.对绝经后原发性高危乳腺癌女性进行抗雌激素治疗。
Breast Cancer Res Treat. 1983;3(1):77-84. doi: 10.1007/BF01806237.
4
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.绝经后II期雌激素受体阳性乳腺癌女性中内分泌治疗与内分泌联合五药化疗的比较
Cancer. 1989 Nov 1;64(9):1819-23. doi: 10.1002/1097-0142(19891101)64:9<1819::aid-cncr2820640910>3.0.co;2-n.
5
[Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].[绝经后复发风险高的乳腺癌患者的辅助内分泌治疗。5. 丹麦乳腺癌协作组（DBCG）77C随机试验的结果]
Ugeskr Laeger. 1991 Aug 12;153(33):2283-7.
6
Adjuvant systemic therapy in primary breast cancer.原发性乳腺癌的辅助性全身治疗。
Acta Chir Scand Suppl. 1984;519:43-53.
7
Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.辅助他莫昔芬治疗对雌激素受体值高的原发性乳腺癌患者的有益作用。
Lancet. 1985 Jan 5;1(8419):16-9. doi: 10.1016/s0140-6736(85)90966-3.
8
Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.人类乳腺癌雌激素依赖性评估。II. 他莫昔芬在晚期原发性和复发性乳腺癌中的临床评估。
Hiroshima J Med Sci. 1984 Jun;33(2):163-6.
9
The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
J Clin Oncol. 1989 Oct;7(10):1474-84. doi: 10.1200/JCO.1989.7.10.1474.
10
[For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].对于患有激素依赖性肿瘤的绝经后女性。芳香化酶抑制剂是新的金标准。
MMW Fortschr Med. 2006 Mar 23;148(12):10.

引用本文的文献

1
A pilot study of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC).胰腺导管腺癌（PDAC）中雌激素受体（ER）表达的一项初步研究。
Transl Gastroenterol Hepatol. 2021 Jan 5;6:9. doi: 10.21037/tgh.2020.02.16. eCollection 2021.
2
A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer.一项关于免疫组织化学测定的激素受体和核特征作为原发性乳腺癌早期复发预测指标的前瞻性分析。
Breast Cancer Res Treat. 1995;36(1):11-21. doi: 10.1007/BF00690180.
3
The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

本文引用的文献

1
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.乳腺癌的组织学分级与预后；对1409例病例的研究，其中359例已随访15年。
Br J Cancer. 1957 Sep;11(3):359-77. doi: 10.1038/bjc.1957.43.
2
Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients.雌激素受体定量与分期作为乳腺癌互补性预后指标：583例患者的研究
Int J Cancer. 1981 Dec;28(6):677-83. doi: 10.1002/ijc.2910280604.
3
Oestrogen-receptor status and sites of metastasis in breast cancer.
类固醇激素受体分析在乳腺癌、子宫内膜癌和卵巢癌中的预测价值。
Med Oncol Tumor Pharmacother. 1986;3(3-4):197-210. doi: 10.1007/BF02934996.
4
Adjuvant systemic therapy: state of the art, 1989.辅助性全身治疗：1989年的最新进展
Breast Cancer Res Treat. 1989 Oct;14(1):3-22. doi: 10.1007/BF01805971.
乳腺癌中的雌激素受体状态与转移部位
Br J Cancer. 1981 Sep;44(3):456-9. doi: 10.1038/bjc.1981.205.
4
Organisation of the Danish adjuvant trials in breast cancer.丹麦乳腺癌辅助治疗试验的组织安排。
Dan Med Bull. 1981 Aug;28(3):102-6.
5
Steroid receptors in adjuvant hormonal therapy for breast cancer.
Can J Surg. 1981 May;24(3):290-3.
6
Rationale for the use of alternating non-cross-resistant chemotherapy.使用交替性非交叉耐药化疗的理论依据。
Cancer Treat Rep. 1982 Mar;66(3):439-49.
7
Symposium on the management of early breast cancer (stages I and II). Part II: Clinical experience with treatment methods. 5. Adjuvant endocrine therapy.
Can J Surg. 1981 Jul;24(4):379-84.
8
Therapeutic effect of tamoxifen related to estrogen receptor level.他莫昔芬的治疗效果与雌激素受体水平相关。
Recent Results Cancer Res. 1980;71:134-41. doi: 10.1007/978-3-642-81406-8_19.
9
Treatment of advanced breast cancer with tamoxifen.他莫昔芬治疗晚期乳腺癌
Recent Results Cancer Res. 1984;91:230-42. doi: 10.1007/978-3-642-82188-2_33.
10
Standardization of steroid receptor assays in human breast cancer--I. Reproducibility of estradiol and progesterone receptor assays.
Eur J Cancer Clin Oncol. 1983 Sep;19(9):1221-9. doi: 10.1016/0277-5379(83)90199-2.